logo
How latest genetic data on fertility may be an indicator of chronic disease onset and longevity

How latest genetic data on fertility may be an indicator of chronic disease onset and longevity

Korea Herald02-05-2025
SINGAPORE, May 2, 2025 /PRNewswire/ -- Latest population studies have cast new light on genetic influences on women's reproductive lifespans and possible markers for the onset of chronic diseases.
Evidence is growing that conditions such as cardiovascular disease, type 2 diabetes, rheumatoid arthritis and neurodegenerative disorders are associated with reduced ovarian reserve, which refers to the number of healthy eggs remaining in a woman's ovaries as she ages.
In contrast, extended ovarian function appears to correlate with general good health and the possibility that greater reproductive success is an indicator of longevity.
The complex genetic interplay between the onset of menstruation and menopause came into sharp focus today at the 2025 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Singapore.
In a keynote address to the Congress, Professor Joop Laven, a world expert in reproductive endocrinology and infertility, suggested reproductive lifespan was associated with "survival".
He is the Professor of Reproductive Medicine at Erasmus Medical Centre, Rotterdam in The Netherlands, Past President of the Dutch Society of Reproductive Medicine, and a lead figure in Genome Wide Association Studies (GWAS).
The GWAS project has identified about 290 genetic determinants of reproductive ageing in a huge cohort of about 500,000 women of European ancestry.
In the project, Professor Laven has explored the genetic basis of hormonal conditions such as polycystic ovary syndrome (PCOS), along with premature ovarian insufficiency, menarche and menopause.
At the ASPIRE Congress, Professor Laven said women with PCOS tended to have the most effective genetic variants for DNA repair providing a "genetic advantage" of fertility beyond the fourth decade of life, when most women have exhausted their natural supply of eggs.
"Studies show PCOS women have better DNA repair and therefore produce better embryos at a later age compared to controls, and they have an extended reproductive life span," he explained.
"Women with PCOS have issues getting pregnant earlier in life. This may reduce the total number of children they have so they do not have a negative trade-off that a high number of children might have.
"Together with their longer lifespan this may represent an evolutionary advantage. Moreover, by having children later in life might reduce the incidence of PCOS in their offspring."
Professor Laven said studies indicated that over time, the gradual accumulation of DNA damage results in the exhaustion of cell renewal capacity and dysfunction in affected organs, ultimately accelerating cell death, commonly referred to as ageing.
"A similar erosion of the genome occurs within the ovaries," he said.
"The extent of DNA maintenance and repair also seems to have a determining effect on susceptibility to conditions including diabetes, cardiovascular disease and neurodegenerative disorders, such as Alzheimer's disease."
Professor Laven said sub-fertility should be monitored as it serves as a sensitive marker for susceptibility to these conditions highlighting the importance of patient follow up among those presenting for assisted reproduction.
"This seems to be in contrast to what most assisted reproductive technology clinics do," he added. "In general, clinics only report live birth rates as success.
"So, in many cases we are not following up our patients who may be susceptible to non-communicable diseases when we have the opportunity to develop preventive health strategies for them."
The ASPIRE Congress at the Suntec Convention and Exhibition Centre in Singapore has brought together over 2,000 scientists, clinicians, nurses and counsellors for a program that will help shape the future of fertility health care in the region and around the world.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The 2025 International Congress of Basic Science Opens in Beijing
The 2025 International Congress of Basic Science Opens in Beijing

Korea Herald

time18 hours ago

  • Korea Herald

The 2025 International Congress of Basic Science Opens in Beijing

BEIJING, July 22, 2025 /PRNewswire/ -- The 2025 International Congress of Basic Science (ICBS) officially kicked off on July 13 at the China National Convention Center in Beijing, gathering the world's brightest scientific minds for a landmark two-week conference. The event brings together four Fields Medalists, three Nobel Laureates, and two Turing Award winners, including Shing-Tung Yau and Andrew Chi-Chih Yao, alongside more than 80 academicians and nearly 1,000 researchers from leading global institutions. President of Tsinghua University Li Luming warmly welcomed scientists from around the world. He emphasized that the ICBS has evolved into a premier platform for global scientists to engage in dialogue and deepen collaboration. Tsinghua University will continue to support Professor Shing-Tung Yau's efforts to advance basic science, and will work together with scientists from all countries to strengthen fundamental research, drive scientific and technological innovation, promote socio-economic development, and jointly create a better future for humanity. Shing-Tung Yau — ICBS President, Fields Medalist, and Chair Professor at Tsinghua University — highlighted recent breakthroughs in mathematics, physics, and information science. He believes a new era driven by theoretical breakthroughs and technological innovations may be dawning. Six trailblazing scientists—Samuel C.C. Ting, Steven Chu, David Gross, Robert Tarjan, Shigefumi Mori, and George Lusztig—were honored with the 2025 Basic Science Lifetime Award, the most prestigious award honoring scientists' contributions to fundamental science. The Congress also awarded 118 Frontiers of Science Awards (FSA) across mathematics, physics, and information science, with winners from over 20 countries. Global AI leaders OpenAI and Meta's FAIR team were also among the recipients. The ICBS was initiated by Shing-Tung Yau in 2023 and is held annually with the theme "Advancing Science for Humanity". Over the next two weeks, nearly 1,000 scholars and students—including over 400 world-leading scientists—will gather at the Beijing Institute of Mathematical Sciences and Applications. Over 500 sessions will cover mathematics, physics, and information science and engineering, with a focus on cutting-edge AI research, interdisciplinary innovation, and frontier theoretical breakthroughs. Beyond academic exchange, ICBS emphasized youth engagement through a diverse range of activities, including the "Tsinghua Day" special event on July 19th. ICBS 2025 celebrates international collaboration and academic exchange in global scientific advancement. "Science thrives on collaboration," said Yau. "This is where the next era of discovery begins."

Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer
Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer

Korea Herald

time2 days ago

  • Korea Herald

Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer

PHILADELPHIA, July 21, 2025 /PRNewswire/ -- Minaris Advanced Therapies is pleased to announce the appointment of Dr. Orla Cloak as Chief Executive Officer. Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President and Head of the Lonza Bioscience business. She holds a Bachelor of Science Degree from University College Dublin and a Doctorate in Microbiology from the University of Ulster. Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented: "On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies." Orla Cloak, Chief Executive Officer, Minaris Advanced Therapies commented:"I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company's strong foundations and drive its next phase of growth." About Minaris Advanced Therapies: Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing. Minaris Advanced Therapies is a portfolio company of Altaris. Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit Media Contact:

Macsen Labs Achieves Breakthrough in Sodium-Ion Battery Chemistry, Files Provisional Patent, and Advances Toward Pilot-Scale Manufacturing
Macsen Labs Achieves Breakthrough in Sodium-Ion Battery Chemistry, Files Provisional Patent, and Advances Toward Pilot-Scale Manufacturing

Korea Herald

time2 days ago

  • Korea Herald

Macsen Labs Achieves Breakthrough in Sodium-Ion Battery Chemistry, Files Provisional Patent, and Advances Toward Pilot-Scale Manufacturing

Video Link: UDAIPUR, India, July 21, 2025 /PRNewswire/ -- Macsen Labs, a manufacturer of APIs, dyes, and specialty chemicals since 1952, has announced a major breakthrough in Sodium-Ion battery technology through the successful R&D-scale synthesis of its high-performance Prussian White, a next-generation cathode material for Sodium-Ion batteries. The company has filed a provisional patent for its proprietary synthesis process. The material has already undergone optimization for battery use at the company's electrochemistry and battery R&D facility and has shown promising results, driving the next phase toward pilot-scale manufacturing. "It's an interesting story, how a pharmaceutical company like ours entered the energy storage space," said Mr. Achal Agrawal, CEO of Macsen Labs and the lead researcher behind the project. "While working on Prussian Blue as a drug for radioactive poisoning, we discovered its derivative — Prussian White, which was emerging as a leading candidate for Sodium-Ion battery cathodes. That moment of curiosity led us down this path." Exactly one year ago, with zero experience in electrochemistry, Macsen's team fabricated a basic pouch cell inside a regular chemistry R&D lab, without specialized equipment. "We had no glovebox, no coater, no calendering machine, just our lab experience and synthesized material," recalled Agrawal. "When that small cell lit up an LED bulb, we knew we had something worth pursuing. That spark led us to establish a full-fledged electrochemistry lab." Today, Macsen's battery R&D facility includes an argon-filled glovebox for inert atmosphere handling, coin and pouch cell fabrication stations, electrode coaters, crimpers, vacuum dryers, and electrochemical testing systems, such as cyclers and potentiostats. With this setup, Macsen can rapidly prototype and test battery cells using its own synthesized materials, significantly reducing development time. The company already operates a pilot-scale chemical synthesis facility, which is now being used to produce Prussian White at a kilogram scale. Through numerous experiments conducted over the last year, the team has gained proficiency in Prussian White chemistry and has achieved what is likely to be one of the finest quality variants produced to date. Through its proprietary process, Macsen has achieved an energy density exceeding 150 mAh/g with Prussian White, which is comparable to Lithium Iron Phosphate (LFP). The material also shows excellent stability, fast sodium-ion mobility due to its open crystalline structure, and compatibility with existing Li-ion cell manufacturing infrastructure. "Performance-wise, it's at par with LFP, but made from abundant, low-cost materials like sodium and iron," said Agrawal. "And these elements are easily available, affordable, and free from geopolitical constraints." This project, originally incubated within Macsen Labs, is now being advanced under a dedicated entity currently under formation — 'Macsen Energy', which will focus exclusively on energy storage innovation and scale-up. "The real potential of sodium-ion batteries lies not just in electric vehicles," said Agrawal. "It lies in stationary energy storage systems that store and manage renewable energy from solar and wind. This is where India's energy transition will happen at scale." Macsen's current Sodium-Ion battery technology, using its Prussian White as cathode paired with a hard carbon anode, is well suited for applications such as battery energy storage systems (BESS) for grid and solar, household backup and inverter systems, short-range EVs, auto-rickshaws, two-wheelers, city buses, rural microgrids, and energy access solutions. The company is now focusing not only on improving cycle life, energy density, charge-discharge rates, and optimizing electrolyte-additive systems, but also on reducing the cost contribution of other components of the battery cell. Macsen aims to develop economical form factors by innovatively combining low-cost battery materials, components, and manufacturing processes, especially for large-scale stationary energy storage. One inherent cost advantage of sodium-ion technology is its use of aluminium in place of copper as the cathode current collector, which would further reduce raw material costs. To demonstrate the performance of Prussian White in commercial large-format cells, Macsen is setting up a pilot-scale cell fabrication line. The company is already sourcing equipment for this and aims to have the pilot-scale production facility operational by early 2026. "We are trying to make a new energy future for India," concluded Agrawal. "Sodium-ion batteries are India's opportunity to build a truly indigenous, scalable, and affordable energy storage ecosystem."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store